Combining Niraparib with Abiraterone Acetate and Prednisone Significantly Improves rPFS in Patients with mCSPC Harbouring BRCA1/2 or Other HRR Gene Alterations By Ogkologos - October 22, 2025 235 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the AMPLITUDE study Source RELATED ARTICLESMORE FROM AUTHOR Weight Loss Treatments Linked to Lower Risk of Obesity-Related Cancers in People Without Diabetes EMA Recommends Granting a Marketing Authorisation for Camizestrant ESMO Calls for the Ring-Fenced Funding of Health Under the 2028-2034 Long-Term Budget of the EU, the Multiannual Financial Framework (MFF) MOST POPULAR ESMO Gynaecological Cancers Congress 2024, 20-22 June, Florence, Italy June 6, 2024 Artist Tattoos Realistic Nipples On Breast Cancer Survivors Post-Mastectomy October 13, 2021 Addressing Racial Disparities in Cancer Care: “Your Stories” Podcast May 12, 2022 EMA Recommends Extension of Indications for Dostarlimab January 23, 2025 Load more HOT NEWS Rebuilding My Life After Cancer and Intensive Treatment: A Survivor’s Story New Super-Microsurgical Procedure May Prevent Lymphedema in Breast Cancer Patients How I Navigated Being a Young Mom During Cancer: A Survivor’s... An apple a day keeps the doctor away
